Amgen Begins Construction on North Carolina Manufacturing Facility
New center comes in response to increasing demand for firm’s medicines
Biotech giant Amgen announced the groundbreaking of its newest biomanufacturing facility, located in Holly Springs, NC. The center, which is expected to be operational by 2025, will help support the growing demand for Amgen's medicines that treat serious illnesses, such as cancer and heart disease.
Amgen's facility will use new technologies that maximize efficiency and help ensure the ability to produce a broad range of medicines that Amgen offers to patients. It will also be built to meet environmental standards, consistent with the company's goal of reducing water usage and waste and achieving carbon neutrality by 2027.
"… Our commitment to continuous improvement and our significant investments in new technologies have enabled us to further accomplish our mission to serve patients while science rapidly evolves," comments Robert A. Bradway, Amgen's chairman and CEO. "We are delighted to be building our newest facility in North Carolina, a major hub for biopharmaceutical innovation."
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
